반응식
[N:1]1[C:10]2[C:5](=[CH:6][CH:7]=[CH:8][CH:9]=2)[CH:4]=[CH:3][C:2]=1[N:11]1[CH2:14][CH:13]([O:15][C:16]2[C:17]([CH:22]3[CH2:27][CH2:26][N:25](C(OC(C)(C)C)=O)[CH2:24][CH2:23]3)=[N:18][CH:19]=[CH:20][N:21]=2)[CH2:12]1.[ClH:35]>CO>[ClH:35].[NH:25]1[CH2:26][CH2:27][CH:22]([C:17]2[C:16]([O:15][CH:13]3[CH2:14][N:11]([C:2]4[CH:3]=[CH:4][C:5]5[C:10](=[CH:9][CH:8]=[CH:7][CH:6]=5)[N:1]=4)[CH2:12]3)=[N:21][CH:20]=[CH:19][N:18]=2)[CH2:23][CH2:24]1참가 물질
4
실험 절차
To tert-butyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-1-carboxylate (400 mg, 0.86 mmol) was added 4 M HCl in MeOH (20 mL). The reaction mixture was stirred at room temperature for 30 min and concentrated. The residue was dried under high vacuum to give 2-(3-((3-(piperidin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline hydrochloride (310 mg, 0.86 mmol, 100% yield) as a white solid. ESI-MS (M+1): 362 calc. for C21H23N5O 361.
후처리
- concentrationconcentrated
- customThe residue was dried under high vacuum
출처 및 근거
- ORD 기록
- ord-b2a6da641005436c839e7bd89f3ffa2c
- 출처 데이터셋
- uspto-grants-2016_06
- 특허 번호
- US09376450B2
연결된 노트
불러오는 중…